Contents Pages by Subject

Healthcare Industry

Subject Photo
Article Image News Link • Global

Drug companies are abandoning the antibacterial business, citing high development costs, low return on investment and, increasingly, a nearly decade-long stalemate with the Food and Drug Administration over how to bring new antibiotics to market.

Join us on our Social Networks:


Share this page with your friends on your favorite social network: